2016 - IPITA - Stem Cell Derived Beta Cells Workshop


Genetic Modification and Genome Editing of Pluripotent Stem Cells

6.3 - Human pancreas development and disease through the lens of pluripotent stem cells

Presenter: Danwei, Huangfu, New York, United States
Authors: Danwei Huangfu


My laboratory is interested in understanding pancreatic development and disease through applying genetic approaches in human pluripotent stem cells (hPSCs), including embryonic and induced pluripotent stem cells (hESCs and hiPSCs). Combining CRISPR/Cas-mediated gene editing and stem cell technologies, our reverse genetics approach has revealed the roles of key transcription factors pancreatic development and diabetes. Using the forward genetics approach, we performed the first genome-wide knockout screen for identification of developmental regulators. We identified novel genes that regulate the formation of definitive endoderm cells, which give rise to most pancreatic cells among other cells in the respiratory and digestive tract. Together our findings establish the use of hPSCs as a genetic model system for studying congenital defects and diabetes.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi